DIAG301-0119: Oncology and Tumor Pathology Module 2
The lectures for this course will be presented in an audio format using a webinar platform.
Enrollment is closed.
Presenters:
Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Rebecca Smedley, DVM, MS, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Course Open: January 2-February 23, 2019
Real Time Sessions (RTS): Wednesdays, January 9, 16, 23, 30, February 6, and 13, 2019; 8:00-10:00 pm ET (USA)
Course RTS Times in Your Area:
World Clock Converter
Level and Prerequisites:
This
advanced course will be open to veterinarians
actively interested in canine and feline oncology and tumor pathology.
Participants should have a strong interest and/or experience in oncology..
VIN CE Course: Open to veterinarians.
This course is approved by RACE for veterinarians . (RACE 22-33449)
Course Information:
This is the second of two modules on oncology and tumor pathology.
This course can be taken independently of the first module
(DIAG300-0818: Oncology and Tumor Pathology I) which is offered in August 2018.
This course will familiarize participants with the current state of tumor
diagnosis and prognosis as well as therapeutic interventions. This course
will cover canine/feline histiocytic diseases, canine/feline soft tissue
sarcomas, canine/feline osteosarcoma, canine melanomas, and canine/feline
mammary tumors.
The pathology segments will discuss the classical histologic criteria to
diagnosis and prognosticate neoplastic diseases including the newest grading
systems. Furthermore, the participants will be introduced to modern molecular
pathology tests that further our prognostic capabilities and help determine
therapeutic protocols, such as immunohistochemical tumor diagnostic and
prognostic panels.
From the clinical oncology perspective, this course will familiarize the
participants with the basic surgical aspects of veterinary oncology including:
routine staging of patients, proper aspirate and biopsy techniques as well
as the preferred approach for a definitive surgery when appropriate.
The remaining lectures are designed to highlight the etiology (with an emphasis
on the latest research regarding genetic aspects of the specific tumor type)
and typical signalment, clinical signs, staging, diagnosis, therapy and
prognosis for specific histologies. A special emphasis will be provided on
the latest research for each cancer type regarding the use of novel targeted
therapies when appropriate.
Week 1 (Real Time Session January 9, 2019):
Tumor Pathology and Clinical Oncology Basics
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Audio
Objectives: Upon completion of this session, the participant should be able to
- submit high quality tumor biopsy samples for microscopic
evaluation, margin evaluation, and advanced molecular
testing from various organs.
- recognize the current histologic grading schemes for
the neoplastic entities discussed.
- understand and integrate advanced molecular testing to
determine tumor prognosis and for therapeutic decision making.
- demonstrate an understanding of the indications for and
differences between incisional and excisional biopsies.
Week 2 (Real Time Session January 16, 2019):
Canine/Feline Histiocytic Diseases
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between
staging and grading while also gaining an appreciation
for general staging recommendations for canine/feline
histiocytic diseases.
- recognize the etiology (with an emphasis on the latest
research regarding genetic aspects of the specific tumor type)
and typical signalment, clinical signs, staging, diagnosis,
therapy and prognosis for canine/feline histiocytic diseases.
- demonstrate an appreciation for the latest research regarding
the use of novel targeted therapies when appropriate.
Week 3 (Real Time Session January 23, 2019):
Canine/Feline Soft Tissue Sarcoma
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between
staging and grading while also gaining an appreciation for
general staging recommendations for canine/feline
soft tissue sarcoma.
- recognize the etiology (with an emphasis on the latest
research regarding genetic aspects of the specific tumor type)
and typical signalment, clinical signs, staging, diagnosis,
therapy and prognosis for canine/feline soft tissue sarcoma.
- demonstrate an appreciation for the latest research regarding
the use of novel targeted therapies when appropriate.
Week 4 (Real Time Session January 30, 2019):
Canine/Feline Osteosarcoma
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between
staging and grading while also gaining an appreciation
for general staging recommendations for canine/feline
osteosarcoma.
- recognize the etiology (with an emphasis on the latest
research regarding genetic aspects of the specific tumor type)
and typical signalment, clinical signs, staging, diagnosis,
therapy and prognosis for canine/feline osteosarcoma.
- demonstrate an appreciation for the latest research
regarding the use of novel targeted therapies when appropriate.
Week 5 (Real Time Session February 6, 2019):
Canine Melanoma
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between
staging and grading while also gaining an appreciation
for general staging recommendations for canine melanoma.
- recognize the etiology (with an emphasis on the latest
research regarding genetic aspects of the specific tumor type)
and typical signalment, clinical signs, staging, diagnosis,
therapy and prognosis for canine melanoma.
- demonstrate an appreciation for the latest research
regarding the use of novel targeted therapies when appropriate.
Week 6 (Real Time Session February 13, 2019):
Canine/Feline Mammary Tumors
Presenters: Dr. med. vet. habil. Matti Kiupel, PhD, DACVP
Craig A. Clifford, DVM, MS, DACVIM (Oncology)
Phil Bergman, DVM, MS, PhD, DACVIM (Oncology)
Rebecca Smedley, DVM, MS, DACVP
Format: Audio
Objectives: Upon completion of this session, the participant should be able to
- demonstrate an understanding of the difference between
staging and grading while also gaining an appreciation
for general staging recommendations for
canine/feline mammary tumors.
- recognize the etiology (with an emphasis on the latest
research regarding genetic aspects of the specific tumor type)
and typical signalment, clinical signs, staging, diagnosis,
therapy and prognosis for canine/feline mammary tumors.
- demonstrate an appreciation for the latest research regarding
the use of novel targeted therapies when appropriate.
Successful completion (scoring 80% or better) on the end-of-course test is required
to earn a certificate of completion for the course.
To learn more about the requirements for earning a CE certificate, please refer to
Receiving Your CE Credit and Course Completion Certificate.
Course Materials: Course materials will be available
in the course library prior to each Real Time Session.
Required Textbook(s): There is no required textbook for this course.
About the Presenters:
Matti Kiupel is a board certified veterinary pathologist
with extensive experience in tumor pathology and molecular pathology.
He is Professor at Michigan State University and runs the histology and
immunohistochemistry laboratory within the Michigan State Veterinary
Diagnostic Laboratory. Dr. Kiupel is an internationally renowned speaker
and has won numerous lecturer awards. He authored 300 peer-reviewed
scientific publications and book chapters and is the editor of the
"Surgical Pathology of Tumors of Domestic Animals" series.
Phil Bergman is a medical oncologist and the Director
of Clinical Studies for VCA at the Katonah-Bedford Veterinary Center,
a 24/7 Specialty/ER center in Westchester County, NY. He is the principal
veterinary investigator for the recently fully licensed canine melanoma
vaccine (Oncept) available from Merial. Dr. Bergman is an adjunct faculty
member of the Memorial Sloan-Kettering Cancer Center and will continue/expand
his cancer vaccine program within the VCA Antech network.
Craig Clifford is a medical oncologist and the Director
of Clinical Studies for Hope Veterinary Specialists in Malvern PA.
Dr. Clifford is a well renowned oncologist who has authored/co-authored over
30 papers and book chapters. He was responsible for the creation of resident
review sponsored by the Veterinary Cancer Society and the Northeast Veterinary
Co-operative Oncology Group. He is a frequent lecturer at major veterinary
meetings in the USA and internationally. Dr. Clifford is currently serving
on the VCS executive board, the ACVIM Exam Rating Committee, the Residency
Training and Credentials Committee and is the Co-chair of the Standards of
Excellence in Residency Education Task Force.
Rebecca Smedley is a board certified veterinary pathologist
with extensive experience in tumor pathology and molecular pathology.
She is an Academic Specialist at the Diagnostic Center for Population and
Animal Health at Michigan State University. Dr. Smedley is first and
collaborating author on a large number of peer-reviewed scientific publications
in the field of tumor pathology and has been an invited speaker on these
topics to national and international scientific conferences. Together with
Dr. Kiupel she is editor of the WSAVA online atlas of Tumor Classification
of Domestic Animals.
Total CE Credit: 12
Tuition: Member $276 ($248 early bird special if enrolled by December 19, 2018)
Non-Member $413 ($372 early bird special if enrolled by December 19, 2018)
Prices are listed in US dollars.
*Enroll in both modules (DIAG300-0818 and DIAG301-0119) of the Oncology and Tumor Pathology course
before August 15, 2018 and receive the discounted enrollment price: Member $469 Non-Member $702
*To ensure participants are ready and prepared for classes,
enrollment will close on January 9, 2019 at 5 pm ET (USA)
or when the maximum number of participants is reached.
*For more information on how online CE works, see the
Participant Resource Center.
To Enroll:
Enrollment is closed.
- Enrollment qualifications: VIN CE courses are open to
VIN member and non-member veterinarians. Veterinarians enrolling in a VSPN CE course
must be a VIN member. Veterinary support staff must be a VSPN member to enroll in a
VSPN CE or a VIN CE course open to VSPN member enrollment.
- Each enrollee must be able to receive emails from @vspn.org
and @vin.com addresses. Email is our major form of communication with participants;
personal emails are highly recommended rather than clinic/hospital email addresses.
- Each person is individually responsible for his/her own registration.
To ensure that all information received is secure and correct, please do not enroll
for a course on behalf of another individual.
- For further assistance call 800-846-0028 ext. 797 or email
CEonVIN@vin.com.
Please include the course title, your full name, and contact information in your correspondence.
"This program (22-33449) is approved by the AAVSB RACE to offer a
total of 12 CE Credits, with a maximum of 12 CE Credits being available to any individual
veterinarian.
This RACE approval is for the subject matter categories of:
Scientific,
using the delivery method of Interactive-Distance: (Web-based, Teleconference or Audio-Conference).
This approval is valid in jurisdictions which recognize AAVSB RACE; however, participants are
responsible for ascertaining each board's CE requirements."
Course withdrawal and refund policy: A complete refund of the paid course price will be
issued when your withdrawal request is received prior to the listed start date of the course.
If you wish to withdraw after the start date please contact the VIN office 800-846-0028 ext. 797
to discuss eligibility for a pro-rated refund.
*For more information on VIN's upcoming CE courses, check the
VIN Course Catalog.
Katherine James, DVM, PhD, DACVIM (SAIM)
VIN Education Director
VIN CE Services:
CEonVIN@vin.com
800-846-0028 or 530-756-4881; ext. 797
or direct line to VIN/VSPN from the United Kingdom: 01 45 222 6154
or direct line to VIN/VSPN from Australia: 02 6145 2357
800.700.4636 | CEonVIN@vin.com | 530.756.4881 | Fax: 530.756.6035
777 West Covell Blvd, Davis, CA 95616
Copyright 2002, Veterinary Information Network, Inc.
|